Cornèr Bank Group Completes Migration of 2.1m Cards to Vestigo’s Card Management Solution
1.7.2021 10:00:00 EEST | Business Wire | Press release
Cornèr Bank Group, issuer of credit and prepaid cards to private individuals and businesses in Europe, has reached a major milestone in its digital transformation journey by completing migration of its card portfolios across all products and markets to a modern, consolidated solution. Vestigo is a European software provider in cards and account-to-account payments space, and its card management system (CMS) is the key component of the overall solution at Cornèr.
Cornèr Bank Group issues more than /2.1/ million credit and prepaid, Visa, Mastercard and Diners cards directly and through partnerships with hundreds of organizations of various sizes in a B2B2C / co-brand business model. The new solution, managed in-house on a single instance, will further improve innovation and quality of service to Cornèr Bank Group’s partners and ultimate cardholders, as well as enhance internal efficiency. Vestigo’s integrated, modular, “multi-everything” solution is fully customer centric, can manage all types of cards, as well as account-to-account payments, and allows for easy integration leveraging 200+ APIs.
This large-scale implementation and migration project was designed to minimize risk and consisted of multiple phases taking into account requirements regarding different markets, products and legacy systems.
Ing. Vittorio Cornaro, Chief Executive Officer of Cornèr Bank Group, said: “Partnering with a trusted partner like Vestigo helps us modernize and consolidate our pan-European card business, which is the key step of our strategy to transform Cornèr into an agile bank delighting our clients and partners every day with best-in-class products and services”
Simone Tettamanti, CIO at Cornèr Banca, added: This complex, large-scale project was an excellent example of two organizations working together successfully as trusted partners towards a common goal, using agile approach. This modern platform will facilitate Cornèr’s business growth and provide us with flexibility to adjust to evolving customer requirements in the future.”
Kata Kamenski, Chief Executive Officer and Co-founder of Vestigo said: “We’re incredibly proud to work with Cornèr, as this further validates Vestigo’s functionality fit, as well as delivery ability fit with sophisticated, innovative financial institutions. Vestigo continues growing strongly, driven by its differentiating capability to drive convergence across cards and account-to-account payments. Our solution is scalable and can be deployed as on-prem, cloud installation or SaaS.”
About Cornèr Bank Group
Founded in Lugano in 1952, the Cornèr Bank Group is an independent Swiss private bank group operating as a full-service bank. Lugano is Switzerland’s third-largest banking centre, after Zurich and Geneva. Active across the whole range of traditional banking services, the Cornèr Bank Group specializes in the private banking sector, as well as in the areas of lending, Visa, Mastercard and Diners Club payment cards (Cornèrcard) and online trading (Cornèrtrader) – the core businesses on which the growth of the Cornèr Bank Group is based. The Cornèr Bank Group comprises the Lugano-based parent bank Cornèr Bank Ltd., the four branches in Chiasso, Geneva, Locarno and Zurich, the branch BonusCard and the affiliates Cornèr Bank (Overseas) Limited, Cornèrcard UK Ltd., Cornèr Europe AG, Diners Club Italia S.r.l. and Dinit d.o.o.
For more information on Cornèr please visit: www.cornergroup.ch
About Vestigo
Vestigo is a founder-owned paytech, fully focused on cards (CMS) and account-to-account payments (PaymentsHub) space. Vestigo’s newest module HolisticPay is a rich payments modernization & convergence layer designed to facilitate managed cards & payments modernization. Our continuously increasing team has more than 130 employees. Vestigo’s modern, modular, customer-centric solution creates value for financial institution clients in payments, issuing and acquiring businesses. We differentiate by bringing the cards and account payments together in a fully customer centric way using modern technology. Vestigo currently supports clients in 7 European countries, with a strong growth strategy into further markets.
For more information on Vestigo please visit: www.vestigo.hr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005043/en/
Contact information
Cornèr Media Contact
Anna Russo, Head of PR
T +41 91 800 53 54
E anna.russo@corner.ch
Vestigo Media Contact:
Valbona Guscic
T +385 91 6392902
E valbona.guscic@vestigo.hr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
